Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

July 15, 2019 sandiegobiotech News Comments Off on Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
/

LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corporate update.

Related Articles

No Picture
News

Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

October 22, 2019 sandiegobiotech News Comments Off on Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

LA JOLLA, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at th… […]

No Picture
News

Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine

September 18, 2019 sandiegobiotech News Comments Off on Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine

LA JOLLA, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that two research studies condu… […]

No Picture
News

Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option

June 25, 2019 sandiegobiotech News Comments Off on Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option

LA JOLLA, Calif., June 25, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the ?Company? or ?Artelo Biosciences?), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the en… […]